Published by Global Banking & Finance Review®
Posted on November 21, 2025
2 min readLast updated: January 20, 2026
Add as preferred source on GoogleDenmark compensates four patients for vision loss linked to Novo Nordisk's Wegovy and Ozempic, citing rare NAION risks.
By Jacob Gronholt-Pedersen
COPENHAGEN (Reuters) -Four patients in Denmark, who experienced vision loss after using Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic, have been granted compensation, the Danish Patient Compensation association said on Friday.
The two drugs, which contain the active ingredient semaglutide, have been linked in very rare cases to a serious eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION), the European Medicines Agency's safety committee noted in June. The condition can cause permanent vision loss.
Following the EMA's findings, Novo Nordisk updated the labels for Wegovy and Ozempic to state that semaglutide may cause NAION in up to 1 in 10,000 patients.
The Danish Patient Compensation association, an independent body that evaluates patient claims on behalf of the state, said on Friday it had ruled in five of the 43 claims it received regarding vision loss allegedly linked to the medications.
Four patients were awarded a combined 800,000 Danish crowns ($123,253), while one claim was dismissed, it said. The state funds compensation payments awarded by the association.
The association described the rulings as "very complex", requiring input from an optic nerve specialist.
A Novo Nordisk spokesperson said: "Patient safety is our top priority," adding that the company "believes that the benefit-risk profile of semaglutide remains favorable."
($1 = 6.4907 Danish crowns)
(Reporting by Jacob Gronholt-Pedersen. Editing by Mark Potter)
Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition that affects the optic nerve, leading to sudden vision loss. It is often associated with various risk factors, including certain medications.
The European Medicines Agency (EMA) is a regulatory body responsible for evaluating and supervising medicinal products in the European Union, ensuring their safety and efficacy.
Explore more articles in the Finance category
